Category Archives: Biotechnology

Ceramist Susan Beiners work has been exhibited in China, France, the Netherlands and across the nation, but it took some persuading to get her to exhibit her creations at Temple Solels latest Art Showcase. After some cajoling, Beiner relented and now her earlier work is on display at Temple Solel through May 31. A reception and talk featuring Beiner are scheduled for 10:30 a.m. Sunday, April 2, at Temple Solel, 6805 E. McDonald Drive, Paradise Valley. Your current subscription does not provide access to this content. Please click the button below to manage your account. kAmp %6>A=6 $@=6= >6>36C D:?46 a_`b[ q6:?6C 😀 2? 2DD@4:2E6 AC@76DD@C 2E pC:K@?2 $E2E6 &?:G6CD:EJD[ w6C36C86C r@==686 @7 u:?6 pCE] w6C 96D:E2?4J E@ D9@H 96C H@C< 2E $@=6= 42>6 7C@> E96 724ED E92E D96 925 ?6G6C 4@?D:56C65 5:DA=2J:?8 96C 2CE 😕 2 DJ?28@8F6 367@C6[ 2D H6== 2D E96 =2C86 D:K6 @7 96C =2E6DE 4C62E:@?D]k^Am kAm(6 E@=5 $FD2? D96 H2D 2 EC6>6?5@FD C6D@FC46 2?5 2 A2CE @7 E96 E6>A=6 2?5 H6 H2?E65 E@ D66 96C H@C2D[ 2 >6>36C @7 E96 pCE o $@=6= 4@>>:EE66] %9:D 😀 E96 7:CDE E:>6 H6G6 925 2 46C2>:4:DE]k^Am kAmx?DA:C65 3J E96 4C27ED >@G6>6?E[ q6:?6C 3682? 4C62E:?8 9:89=J 56E2:=65[ 2?5 2E E:>6D … Continue reading →

Many intriguing articles have been written about investing in biotechnology. Biotechnology investment has been referenced by many knowledgeable and respectable authors as controversial, out of favor, and even sexy (this article by Stephen Simpson, CFA, is must read). Surviving current trends in biotechnology stock price manipulation can be both stressful and disappointing. This leaves us all to wonder is it even worth it to try speculative biotechnology as an investment option? StrongBio believes it is worth it, even if it results in losses that are hard to endure. In the end, contributions to healthcare from growing sources of capital are extremely important for improved patient care (termed supply-side capital). As these contributions have grown, however, so too has waste. With proper selection, timing, and diversification (three pillars of biotechnology investment), the common retail investor can eventually be financially rewarded as philanthropic goals of the population are met. Simply put, biotechnology companies focus on drug development aiming to treat an unmet or under-met disease or medical condition. Companies that have succeeded have net sales in the tens of billions and total market values in the hundreds of billions of dollars. Speculative biotechnology companies, in contrast, differ from proven top biotechnology companies … Continue reading →

The Nasdaq Composite Index rose Wednesday, buoyed by broad advances at biotechnology and IT companies, after the Federal Reserve decided to raise interest rates for the second time in three meetings. The technology-heavy index rose 0.7% to 5,900.05, its fifth advance in the last six sessions. The benchmark index settled just below all-time highs. With the gain, the Nasdaq has returned nearly 10% for the year, outpacing the S&P 500 Index and Dow Jones Industrial Average. A total of 2,009 companies listed on the Nasdaq reported gains, versus 888 that finished lower and 229 that went unchanged. A total of 166 companies reported new highs, versus 47 that set new lows. Health stocks listed on the S&P 500 rose more than 1%, with pharmaceuticals, biotechnology and life sciences leading the rally. Information technology also advanced 0.6% as a sector. Advertising The Nasdaq Biotechnology Index rose 1.5% to 3,162.82. The Federal Reserve raised its benchmark interest rate by a quarter point to 1% in a move that was widely anticipated by the markets. Policymakers continue to expect three rate increases this year, putting the central bank on course for two additional adjustments in 2017. In terms of upcoming releases, the U.S. … Continue reading →

On March 9, 2017, the National Academies of Sciences, Engineering, and Medicine (National Academies) published a report entitled Preparing for Future Products of Biotechnology, prepared by the Committee on Future Biotechnology Products and Opportunities to Enhance Capabilities of the Biotechnology Regulatory System (Committee). The Committee was asked to describe the possible future products of biotechnology that will arise over the next five to ten years, as well as provide some insights that can help shape the capabilities within the U.S. Environmental Protection Agency (EPA), the U.S. Food and Drug Administration (FDA), and the U.S. Department of Agriculture (USDA) as they move forward. According to the Committee, agencies may be overwhelmed by the number and diversity of new biotechnology products. The Committee states that the agencies should increase their scientific capabilities, tools, and expertise in key areas of expected growth. The report reflects the Committees deliberations regarding the future products of biotechnology that are likely to appear on the horizon, the challenges that the regulatory agencies might face, and the opportunities for enhancing the regulatory system to prepare for what might be coming. The Committee reached consensus on conclusions and recommendations that are based on extensive information gathering, Committee discussions, and … Continue reading →

Sam Konduros(Photo: Provided) Sam Konduros, a former executive director of Greenville Health Systems Research Development Corporation, was named on Monday as the new president and CEO of the S.C. Biotechnology Industry Organization. SCBIO is a statewide, non-for-profit that represents and organizes innovators in medicine, medical devices and biomaterials. Konduros is a currently a member of the SCBIO Board of Directors. I greatlyappreciate the SCBIO boardspassion forservingand advancing South Carolinas rapidly growing life sciences community and industry sector, and for their vote of confidence in my leadership capabilities for the organization going forward, Konduros said in a statement. Architecture and design firm adds new hire to Greenville office Verizon looks to fill 100 positions at new telesales center in Greenville Konduros, a business leader and biomedical and economic development consultant, is the founder of SK Strategies LLC, launched in 2004, and has led a number of state economic development efforts. He was the founding president and CEO of theUpstate S.C. Alliance, and is a former chairman for the Greenville Chamber of Commerce and a former committee member of the S.C. Chamber of Commerce. Konduros has a law degree from the University of South Carolina and an undergraduate degree from Clemson University. … Continue reading →

PESHAWAR: The Khyber Pakhtunkhwa Directorate of Science and Technology in collaboration with the Institute of Integrative Biosciences, Cecos University, organised a Biotech Young Leaders Conference at a local hotel here on Sunday. The conference brought together the student community of life sciences under one roof to discuss the future of biotechnology in the country, says a press release. Faisal Khan, director of the institute, said that it was important to organise such events for young students to divert their minds from pessimism to optimism. The event was also attended by the science and technology director, Zahoorul Haq. We may be lagging behind when it comes to information technology, but we are not going to stay behind in emerging technologies such as synthetic biology as the provincial government is working on a policy to promote science and technology in the province, he said. The statement said that a team of young biotechnologists who represented the country at the international iGEM competition in Boston and bagged a gold medal was also funded by the S&T directorate. A three-year extension of the iGEM fellowship was also announced at the end of the conference. In the end, Dr Shafeequr Rehman, CEO of Rehman Medical … Continue reading →

Written by ANJALI MARAR | Pune | Published:March 11, 2017 2:20 am GOOD TIMES seem to have arrived at least for the countrys biotechnology sector that has been awarded the highest budgetary hike in this years union budget. Though there has been an overall 10 per cent hike in the total budget allotted for science, biotechnology and earth sciences this year, it is the Department of Biotechnology (DBT) that has won the jackpot by being awarded the highest hike to Rs 2,222 crore as opposed to Rs 1,917 crore received last year. While Rs 37,435 crore has been allotted for science and technology this year, the same stood at Rs 33,467 crore in the 2016-2017 budget. Scientists in the city have given mixed reactions to this years budget as some are of the opinion that there is little clarity or specific plans mentioned for taking forward the ambitious Make in India and Start-Up India initiatives from these research fields. Watch what else is making news: Its indeed a welcome move that DBT has been awarded higher amount of money this year. However, the budget is disappointing as there was no concrete plan or budgetary allocations for Start-Ups made, said Rajendra … Continue reading →

Federal US agencies need to prepare for greater quantity, range of biotechnology products Science Daily A profusion of biotechnology products is expected over the next five to 10 years, and the number and diversity of new products has the potential to overwhelm the U.S. regulatory system, says a new report from the National Academies of Sciences ... See the original post here: Federal US agencies need to prepare for greater quantity, range of biotechnology products - Science Daily … Continue reading →

Puma Biotechnology Inc(PBYI) Indepth Earnings, EPS and Estimated Revenue Guidance give detailed picture on the performance.Puma Biotechnology Inc has received $-1.92 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-2.48 while the top line estimate is $-1.2 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 12.33%. Puma Biotechnology Inc results fell short with a surprise EPS of -1% or $-0.02. The Actual EPS was $-2.02 compared to the Estimated EPS of $-2 during its most recent quarterly earnings. Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Puma Biotechnology Inc was Reiterated by RBC Capital Mkts on Mar 2, 2017 to Sector Perform, Lowers Price Target to $ 17 from a previous price target of $48 . Company has reported several Insider transactions to the SEC, on Jan 24, 2017, Steven Lo (Chief Commercial Officer) sold 2,290 shares at 33.24 per share price.On Jan 24, 2017, Charles R Eyler (officer … Continue reading →

While the broader stock market fell Monday, many biotech shares continued to outperform. The big mover was TG Therapeutics Inc. TGTX, -6.88% which soared 90% after releasing positive results from its Phase 3 clinical trial of its treatment for high-risk leukemia patients. The stock closed up $4.85 to $10.20 on 33.7 million shares, which is 34 times its daily average. The stock blew through several layers of resistance, but pulled back at the close below resistance from the April high at around $10.50. A breakthrough there should get the stock to $13 and then $15. Support is at the days low of $9.10 and then $8. Short interest of 22 times its average volume could accelerate the advance. Concert Pharmaceuticals Inc. CNCE, +5.11% rocketed 62% Monday on news that Vertex Pharmaceuticals Inc. VRTX, +0.94% will be acquiring the companys cystic fibrosis drug, CTP-656. The stock closed at $15.64, up $5.99, at around the mid-range of the days action, which bodes well for a follow-through. Volume of 10.5 million shares was more than 85 times its average. Watch for a retest the days intraday high at $18.48, a breakthrough that could get the stock moving to test its highs from November … Continue reading →